S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
'Civil War’ continues box-office campaign at No. 1
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

$1.75
-0.06 (-3.31%)
(As of 04/19/2024 ET)
Today's Range
$1.71
$1.86
50-Day Range
$1.68
$2.43
52-Week Range
$1.24
$12.00
Volume
186,744 shs
Average Volume
250,720 shs
Market Capitalization
$33.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Fortress Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,614.3% Upside
$30.00 Price Target
Short Interest
Bearish
14.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.57) to ($5.57) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.14 out of 5 stars

Medical Sector

500th out of 909 stocks

Pharmaceutical Preparations Industry

225th out of 424 stocks

FBIO stock logo

About Fortress Biotech Stock (NASDAQ:FBIO)

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

FBIO Stock Price History

FBIO Stock News Headlines

The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
Why Fortress Biotech Shares Are Tumbling Today
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
Employees
187
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$75.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,614.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-60,640,000.00
Pretax Margin
-181.79%

Debt

Sales & Book Value

Annual Sales
$84.51 million
Book Value
$0.10 per share

Miscellaneous

Free Float
12,811,000
Market Cap
$33.67 million
Optionable
Optionable
Beta
1.51
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 69)
    Executive Chairman, President & CEO
    Comp: $942.78k
  • Mr. Michael S. Weiss Esq. (Age 58)
    Vice Chairman & Executive Vice Chairman of Strategic Development
    Comp: $167.92k
  • Mr. David Jin (Age 33)
    CFO & Head of Corporate Development
    Comp: $976.96k
  • Dr. George C. Avgerinos (Age 70)
    Senior Vice President of Biologics Operations
    Comp: $386.49k
  • Mr. Samuel Berry
    General Counsel & Corporate Secretary

FBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings
or view top-rated stocks.

What is Fortress Biotech's stock price target for 2024?

3 brokerages have issued 12 month target prices for Fortress Biotech's stock. Their FBIO share price targets range from $5.00 to $75.00. On average, they expect the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,614.3% from the stock's current price.
View analysts price targets for FBIO
or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2024?

Fortress Biotech's stock was trading at $3.01 on January 1st, 2024. Since then, FBIO shares have decreased by 41.9% and is now trading at $1.75.
View the best growth stocks for 2024 here
.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,880,000 shares, an increase of 8.7% from the March 15th total of 1,730,000 shares. Based on an average trading volume of 392,200 shares, the days-to-cover ratio is currently 4.8 days. Currently, 14.1% of the company's stock are short sold.
View Fortress Biotech's Short Interest
.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FBIO earnings forecast
.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) posted its earnings results on Thursday, March, 28th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter. The biopharmaceutical company earned $19.95 million during the quarter, compared to analysts' expectations of $14.46 million. Fortress Biotech had a negative net margin of 74.12% and a negative trailing twelve-month return on equity of 770.86%.

When did Fortress Biotech's stock split?

Shares of Fortress Biotech reverse split on Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FBIO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners